

COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW WASHINGTON
WASHINGTON, DC 20004-2401 NEW YORK
TEL 202.662.6000 SAN FRANCISCO
FAX 202.662.6291 LONDON
WWW.COV.COM BRUSSELS

LANNY A. BREUER
TEL 202.662.5538
FAX 202.778.5538
LBREUER@COV.COM

September 4, 2007

CONFIDENTIAL TREATMENT REQUESTED

VIA E-MAIL

Representative John D. Dingell
Chairman
United States House of Representatives
Committee on Energy and Commerce
2328 Rayburn House Office Building
Washington, DC 20515-6143

Representative Bart Stupak
Chairman
United States House of Representatives
Committee on Energy and Commerce
Subcommittee on Oversight and Investigations
2352 Rayburn House Office Building
Washington, DC 20515-6143

Re: Request to Johnson & Johnson

Dear Representatives Dingell and Stupak:

This letter is the first response to the Committee on Energy and Commerce's August 13, 2007 request to Johnson & Johnson.

Enclosed please find a copy of the FDA's warning letter to Richard D. Anderson of Cordis Corporation dated April 1, 2004. This warning letter responds to the first item in your August 13 letter. We are continuing to gather responsive documents to your remaining requests.

We have enclosed a complete copy of the FDA warning letter, without the redactions present on the version published on the FDA website. Cordis Corporation considers the material contained within these documents to be highly sensitive and confidential and to contain proprietary business information. The unauthorized public disclosure of this material could adversely affect the company and the products and processes referenced in the documents. Accordingly, we believe that these documents constitute "trade secrets and commercial or financial information which is privileged or confidential," as defined in 21 C.F.R. § 20.61, and confidential or trade secret information subject to the restrictions contained in the Trade Secrets

COVINGTON & BURLING LLP

Representative John D. Dingell

Representative Bart Stupak

September 4, 2007

Page 2

CONFIDENTIAL TREATMENT REQUESTED

Act, 18 U.S.C. § 1905. We consider these documents to be protected from public disclosure under the exemptions to the Freedom of Information Act, 5 U.S.C. §552, and under section 301(j) of the Food, Drug, and Cosmetic Act, 21 U.S.C. § 331(j). Therefore, we request that the Committee provide us prior notice and an opportunity to object before any public disclosure of this material.

We look forward to working with you and your staff as you review this information. Please do not hesitate to contact me with questions or comments.

Sincerely,

Lanny A. Breuer / RAR

Lanny A. Breuer

Enclosure (CRD0000001-09)